<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192357</url>
  </required_header>
  <id_info>
    <org_study_id>M3F01</org_study_id>
    <nct_id>NCT04192357</nct_id>
  </id_info>
  <brief_title>A Randomised Controlled Trial of a Weight Loss Maintenance Program for Adults With Obesity</brief_title>
  <official_title>A Randomised Controlled Trial of a Weight Loss Maintenance Program for Adults With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Health Technology and Services Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade do Porto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of a weight loss program (M3F) in&#xD;
      maintaining long-term weight loss (at least 5% of initial body weight loss at 72 weeks),&#xD;
      compared to a low carbohydrates diet (low-carb diet) in obese adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight</measure>
    <time_frame>72 weeks</time_frame>
    <description>Difference between the intervention and control group in the change of weight from baseline to the end of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total fat mass</measure>
    <time_frame>72 weeks</time_frame>
    <description>Difference between the intervention and control group in the change of total fat mass, measured by bioimpedance analysis (BIA) from baseline to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>72 weeks</time_frame>
    <description>Difference between the intervention and control group in the change of waist circumference from baseline to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>72 weeks</time_frame>
    <description>Change in body mass index (calculated as change in kg/m^2, weight in kilograms, height in meters) from baseline to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>72 weeks</time_frame>
    <description>Difference between the intervention and control group in the change in systolic and diastolic blood pressure from baseline to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal microbiota</measure>
    <time_frame>72 weeks</time_frame>
    <description>Difference between the intervention and control group in the change of intestinal microbiota from baseline to the end of follow-up.&#xD;
Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>M3F program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the M3F program. The M3F program is divided into three phases method, being the first two of weight loss and the third phase of weight maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-carb diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases method, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>M3F program</intervention_name>
    <description>72-week behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 and 5 months, respectively; and a third phase of weight maintenance).</description>
    <arm_group_label>M3F program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low-carb diet</intervention_name>
    <description>72-week behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance).</description>
    <arm_group_label>Low-carb diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and premenopausal women (self-reported) aged 18 to 65 years&#xD;
&#xD;
          -  BMI ≥ 30 kg/m2 and ≤ 39.9 kg/m2&#xD;
&#xD;
          -  Interested in being enrolled in a weight loss program&#xD;
&#xD;
          -  Available to comply with study protocol and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, breastfeeding or planning to become pregnant within the study period.&#xD;
&#xD;
          -  Subjects with chronic inflammatory bowel disease (clinical history of Crohn's disease,&#xD;
             ulcerative colitis, irritable colon and diverticulitis)&#xD;
&#xD;
          -  Subjects with hormonal or thyroid pathology (hyper and hypothyroidism where TSH is not&#xD;
             within normal range)&#xD;
&#xD;
          -  Subjects with renal impairment&#xD;
&#xD;
          -  Subjects with chronic liver disease other than non-alcoholic hepatic steatosis&#xD;
&#xD;
          -  Subjects with autoimmune diseases and/or chronic use of corticosteroids.&#xD;
&#xD;
          -  Use of weight loss medications/other nutritional supplements&#xD;
&#xD;
          -  Subjects with psychiatric or neurological illness&#xD;
&#xD;
          -  Subjects sensitive to any component of supplements&#xD;
&#xD;
          -  Subjects with surgery or hospitalization in the last 30 days&#xD;
&#xD;
          -  Subjects prescribed with 5 or more drugs&#xD;
&#xD;
          -  Previous attempt to lose weight in the last month and/or weight loss of more than 10kg&#xD;
             in the 3 months prior to the start of the study&#xD;
&#xD;
          -  Subjects with excessive alcohol consumption (self-reported: drinking more than 3&#xD;
             glasses of wine/day - or equivalent)&#xD;
&#xD;
          -  Subjects with history of drug, alcohol or other substances abuse.&#xD;
&#xD;
          -  Eating behavior disorders&#xD;
&#xD;
          -  Pacemaker carrier&#xD;
&#xD;
          -  Urinary incontinence&#xD;
&#xD;
          -  Vegetarians or vegans&#xD;
&#xD;
          -  Subjects underwent bariatric surgery&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Altered blood clotting&#xD;
&#xD;
          -  Severe heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Conceição Calhau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CINTESIS, NOVA Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Conceição Calhau, PhD</last_name>
    <phone>00351 218803035</phone>
    <phone_ext>20401</phone_ext>
    <email>ccalhau@nms.unl.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>André Rosário, PhD</last_name>
    <phone>00351 218803035</phone>
    <phone_ext>20401</phone_ext>
    <email>andre.rosario@nms.unl.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NOVA Medical School, NOVA University of Lisbon</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-056</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conceição Calhau, PhD</last_name>
      <phone>00351 218803035</phone>
      <phone_ext>20401</phone_ext>
      <email>ccalhau@nms.unl.pt</email>
    </contact>
    <contact_backup>
      <last_name>André Rosário, PhD</last_name>
      <phone>00351 218803035</phone>
      <phone_ext>20401</phone_ext>
      <email>andre.rosario@nms.unl.pt</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

